Spruce Biosciences, Inc. (SPRB)
NASDAQ: SPRB · Real-Time Price · USD
0.00
+0.0190 (0.03%)
Apr 13, 2026, 9:33 AM EDT - Market open
Spruce Biosciences Stock Forecast
Stock Price Forecast
The 5 analysts that cover Spruce Biosciences stock have a consensus rating of "Buy" and an average price target of $170.1, which forecasts no change in the stock price over the next year. The lowest target is $37.5 and the highest is $283.
Price Target: $170.1 (0.00%)
Analyst Consensus: Buy
* Price targets were last updated on Mar 10, 2026.
Analyst Ratings
The average analyst rating for Spruce Biosciences stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 3 | 3 | 3 | 3 | 3 |
| Hold | 5 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citizens | Citizens | Buy Maintains $180 → $170 | Buy | Maintains | $180 → $170 | n/a | Mar 10, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $200 | Strong Buy | Reiterates | $200 | n/a | Mar 10, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $220 → $200 | Strong Buy | Maintains | $220 → $200 | n/a | Feb 19, 2026 |
| Oppenheimer | Oppenheimer | Buy Initiates $283 | Buy | Initiates | $283 | n/a | Dec 23, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $220 | Strong Buy | Initiates | $220 | n/a | Dec 22, 2025 |
Financial Forecast
Revenue This Year
51.17M
Revenue Next Year
10.55M
from 51.17M
Decreased by -79.38%
EPS This Year
-37.45
from -50.83
EPS Next Year
-11.46
from -37.45
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 158.0M | 16.1M | |
| Avg | 51.2M | 10.6M | |
| Low | n/a | 5.5M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | -68.5% | |
| Avg | - | -79.4% | |
| Low | - | -89.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -21.26 | 12.28 | |
| Avg | -37.45 | -11.46 | |
| Low | -63.29 | -27.62 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.